WebDoctor Encyclopedia

Article

Intravesical BCG Therapy

What is intravesical BCG therapy?

Intravesical BCG therapy is a treatment for early bladder cancer in which a liquid containing live, weakened bacteria is put directly into the bladder through a thin tube (catheter). “Intravesical” means “inside the bladder”. BCG stands for Bacillus Calmette-Guerin, the same bacterium used in the tuberculosis (TB) vaccine.

BCG works by stirring up the immune system in the lining of the bladder. The immune cells that gather in response attack the bladder cancer cells. It is therefore a type of immunotherapy, though a very different one from the modern immunotherapy drugs given into a vein.

BCG is used after surgery to remove bladder tumours through the urethra (a procedure called transurethral resection of bladder tumour, or TURBT). It is given to people with non-muscle-invasive bladder cancer that has a high or intermediate risk of coming back or spreading into the bladder muscle. It is not a treatment for cancer that has already grown into the muscle wall.

A brief history

The BCG vaccine was developed in France by Albert Calmette and Camille Guerin and first used in 1921. Doctors later noticed hints that BCG might affect cancer. In 1976, Alvaro Morales and colleagues in Canada reported that BCG placed in the bladder reduced the return of superficial bladder tumours. Further trials in the 1980s and 1990s, including studies of maintenance treatment, established BCG as the standard treatment for high-risk early bladder cancer.

1. Key facts at a glance

Feature Details
Type of treatment Immunotherapy given into the bladder
Main use High-risk and intermediate-risk non-muscle-invasive bladder cancer, including carcinoma in situ
How it is given Liquid passed into the bladder through a catheter and held for up to 2 hours
Induction course Once a week for 6 weeks
Maintenance Short courses repeated for 1-3 years
Setting Outpatient clinic
Main side effects Burning on passing urine, needing to pass urine often, blood in urine, flu-like symptoms

2. How it works

Triggering a local immune response

When BCG is placed in the bladder, the bacteria stick to the bladder lining and are taken up by cells there, including cancer cells. This sets off a strong local inflammation. Immune cells, including T cells and natural killer cells, flood into the bladder wall and release chemical messengers. These immune cells then recognise and destroy cancer cells.

Why the bladder is suited to this

Feature Benefit
Direct contact The treatment reaches the tumour bed and lining without passing through the blood
Hollow organ The liquid can be held in place for a set time
Easy access A catheter can be passed through the urethra in minutes
Little reaches the rest of the body Fewer whole-body side effects than many other treatments

Why maintenance matters

A single course of BCG triggers a strong but temporary response. Repeated short courses over months and years appear to keep the immune system primed. Trials have shown that maintenance treatment is needed to get the full benefit (Lamm et al., 2000; Sylvester, van der Meijden and Lamm, 2002).

3. Who it is for

Conditions treated

Condition Role of BCG
Urothelial carcinoma of the bladder Standard after TURBT for high-risk non-muscle-invasive cancer and carcinoma in situ; an option for intermediate risk
Upper tract urothelial carcinoma Occasionally given into the kidney drainage system for carcinoma in situ, in specialist centres

Risk groups

Risk group Examples Usual approach
Low risk Small, single, low-grade Ta tumour Single dose of chemotherapy into the bladder after surgery; BCG not usually needed
Intermediate risk Multiple or recurring low-grade tumours Chemotherapy or BCG into the bladder, often with 1 year of BCG maintenance
High risk High-grade tumours, T1 tumours, carcinoma in situ BCG induction and maintenance for 1-3 years
Very high risk Certain aggressive features Removal of the bladder may be discussed as an alternative

Who should not have BCG

Situation Reason
Weakened immune system Risk of BCG infection spreading through the body
Visible blood in urine or a urine infection on the day Higher risk of BCG entering the bloodstream
Recent traumatic catheter insertion Same reason
Within 2 weeks of TURBT The bladder lining needs to heal first
Pregnancy or breastfeeding Not recommended

4. Before treatment

Step Why it is done
TURBT Removes visible tumours and confirms the stage and grade
Repeat TURBT Often recommended for T1 tumours to make sure nothing was missed
Urine test Checks for infection before each treatment
Medicines review Some medicines, such as steroids or immune-suppressing drugs, may be a concern
Planning visit A nurse explains the treatment and safety measures

On the day

You are usually asked to limit fluids for a few hours before treatment, so the bladder does not fill too fast and the BCG is not diluted. Empty your bladder just before the catheter is put in.

5. What to expect: step by step

Step What happens
1. Urine check A quick dipstick test for infection or blood
2. Catheter A thin, lubricated tube is passed through the urethra into the bladder
3. Instillation The BCG liquid runs slowly into the bladder
4. Catheter removed Usually straight away
5. Hold You keep the liquid in for up to 2 hours
6. Pass urine Sitting down, to avoid splashes
7. Clean up Follow safety advice for the next 6 hours

Treatment schedule

Phase Typical timing
Induction Weekly for 6 weeks, starting 2-4 weeks after TURBT
First check Cystoscopy about 3 months after starting
Maintenance Weekly for 3 weeks at 3, 6 and 12 months, then every 6 months for up to 3 years

Maintenance schedules vary. In a large European trial, 3 years of full-dose maintenance reduced recurrences more than 1 year in high-risk patients, while 1 year was enough for intermediate-risk patients (Oddens et al., 2013).

Safety at home

Precaution Why
Sit to pass urine for 6 hours Avoids splashing live bacteria
Pour bleach into the toilet after passing urine Leave for about 15 minutes before flushing, as advised by your team
Wash hands and genitals afterwards Removes bacteria from skin
Use condoms for a week after each treatment Protects your partner
Drink plenty after the 6 hours Helps flush the bladder

6. Side effects and risks

Common side effects

Side effect What to expect
Burning on passing urine Very common for 1-2 days after each treatment
Needing to pass urine often or urgently Very common
Blood in urine Usually mild
Flu-like symptoms Tiredness, aches and mild fever for a day or two
Discomfort in the lower tummy Usually mild

How common are side effects?

In a large European trial, about 7 in 10 people reported at least one side effect. The most frequent were bladder irritation (in about one-third) and feeling generally unwell (about 1 in 6). About 8% stopped treatment because of side effects, mostly in the first year (Brausi et al., 2014).

Serious but uncommon risks

Risk What to look for
BCG infection in the body High fever over 38.5C, shivering, feeling very unwell; needs urgent treatment
Joint pain or swelling Reactive arthritis
Infection of the prostate, testicles or kidney Pain or swelling in these areas
Bladder shrinkage Rare, after long courses

When to get urgent help

Contact your team or emergency services straight away if you develop a high temperature, shivering, symptoms that last more than 48 hours, or feel very unwell. BCG infection is treated with anti-TB antibiotics.

7. Results and outlook

Study Main finding
SWOG maintenance trial, 550 patients randomised Median recurrence-free survival was about 77 months with maintenance BCG versus about 36 months without it (Lamm et al., 2000)
Meta-analysis, 24 trials BCG reduced the odds of progression to muscle-invasive cancer by about 27%, but only when maintenance was given (Sylvester, van der Meijden and Lamm, 2002)
EORTC dose and duration trial, 1,355 patients For high-risk patients, 3 years of full-dose maintenance lowered recurrence compared with 1 year; for intermediate risk, 1 year was enough (Oddens et al., 2013)
EORTC side effects analysis Side effects were similar regardless of dose or duration (Brausi et al., 2014)

What the results mean

BCG is very effective at preventing early bladder cancer from coming back and reduces the chance of it spreading into the bladder muscle. It allows many people to keep their bladder. However, it does not work for everyone. Regular cystoscopy checks are essential to pick up any recurrence early.

If BCG does not work

If the cancer comes back despite adequate BCG, it is called BCG-unresponsive. Options may include surgery to remove the bladder, an immune checkpoint inhibitor, newer drugs or gene therapies given into the bladder, or a clinical trial.

8. Recovery and aftercare

Tip Why
Rest on the day of treatment Flu-like symptoms are common
Use simple painkillers if advised Ease aches and fever
Drink plenty of fluids after the first 6 hours Helps ease bladder irritation
Keep a record of symptoms Helps the team decide whether to adjust treatment
Do not miss cystoscopy appointments Detect recurrence early

Follow-up

Cystoscopy (a camera check of the bladder) is usually done every 3 months for the first 2 years, then less often. Urine tests for cancer cells and scans of the upper urinary tract may also be done. Follow-up usually continues for many years.

Coping with bladder symptoms

Bladder irritation tends to be worse in the later weeks of induction and during maintenance courses. Planning treatment days so that you are near a toilet, carrying a spare set of underwear and using pads for leaks can make things easier. Medicines that calm the bladder or ease burning may help, so ask your team rather than putting up with severe symptoms.

Stopping smoking

Smoking is a major cause of bladder cancer and increases the chance of it coming back. Stopping smoking at any point helps, and support is available.

9. Alternatives

Alternative When it is considered
Chemotherapy into the bladder (such as mitomycin or gemcitabine) Low or intermediate risk, or when BCG is not available
Surgery to remove the bladder (radical cystectomy) Very high risk, or BCG has not worked
Immune checkpoint inhibitors Some BCG-unresponsive carcinoma in situ for people who cannot or will not have cystectomy
Clinical trials Newer treatments into the bladder

10. Frequently asked questions

Question Answer
Will BCG give me TB? Very rarely, BCG infection can occur; it is treated with antibiotics
Is it safe for my family? Yes, with simple hygiene precautions
Can I have sex? Use condoms for a week after each treatment
Can I go to work? Many people work, though the day after treatment can be tiring
What if there is a BCG shortage? Your team may change the schedule or use alternatives
Does BCG protect against other infections? It is not given for this purpose
Will the catheter hurt? It may be uncomfortable for a moment; anaesthetic gel is used
Can I drive home? Usually yes, though some people prefer to be driven
How long will treatment last? Usually 1-3 years including maintenance

11. Questions to ask your care team

  • What is my risk group?
  • How many maintenance courses will I need?
  • What should I do if side effects become severe?
  • What precautions should I take at home?
  • What happens if BCG does not work?
  • How often will I need cystoscopy?

Resources

  1. Brausi, M. et al. (2014) ‘Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG’, European Urology, 65(1), pp. 69-76.
  2. Lamm, D.L. et al. (2000) ‘Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study’, Journal of Urology, 163(4), pp. 1124-1129.
  3. Oddens, J. et al. (2013) ‘Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance’, European Urology, 63(3), pp. 462-472.
  4. Sylvester, R.J., van der Meijden, A.P. and Lamm, D.L. (2002) ‘Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials’, Journal of Urology, 168(5), pp. 1964-1970.
  5. National Cancer Institute (2026) Bladder Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.